Abstract
The routine COVID-19 surveillance in Malawi that relied on retrospective reporting could not efficiently steer timely measures to the rapidly evolving pandemic. To monitor real-time changes in infections and inform the COVID-19 response, we implemented an active sentinel surveillance system from July to December 2022. SARS-CoV-2 symptomatic and asymptomatic patients in selected health facilities (HFs) and anyone aged ≥5 years entering at Point of Entry (PoEs) sites were eligible to participate. Self-reported epidemiological and clinical data, and nasopharyngeal specimens were collected from 9,305 participants. A higher overall SARS-CoV-2 RT-PCR positivity rate was observed at HFs, 8.9% among symptomatic and 6.5% among asymptomatic patients, versus 3.5% at PoEs. The positivity trends among symptomatic and asymptomatic patient groups showed a similar pattern throughout the period. This active surveillance complemented routine surveillance, especially during a low incidence period and highlighted the need to target both symptomatic and asymptomatic population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This survey was supported by the President's Emergency Plan for AIDS Relief (PEPFAR) with CARES Act funding through the US Centers for Disease Control and Prevention (CDC) under the terms of Cooperative Agreement NU2GGH002038 with implementation led by International Training and Education Center for Health (I-TECH) Malawi, University of Washington, Lilongwe, Malawi The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the official position of the funding agency.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approvals were granted by the National Health Services Research Council (Reference NHSRC # 22/04/2896) and the protocol was reviewed by CDC, deemed not research, and was conducted consistent with applicable federal law and CDC policy
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.